Cerasela is a seasoned Medical Director with over 20 years of experience in the pharmaceutical industry. She has extensive experience in clinical study operations and execution, including Electronic Data Capture (EDC), clinical monitoring, and Good Clinical Practice (GCP) across all stages of development.

 

Previously, Cerasela has served as Senior Medical Director at Axcella and Medical Director at both Akros Pharma Inc. and Nabriva Therapeutics PLC overseeing clinical development from Phase I to III across endocrine, dermatology, cardiac, and rheumatology areas.  Her contributions to the Phase II and Phase III studies supported the approval of three drugs and one medical device.

Cerasela earned her medical degree from Universitatea de Medicină și Farmacie “Carol Davila” in Bucharest, Romania, where she practiced medicine for eight years across various fields, including Emergency Medical Care and Occupational Medicine.

​

​

Richard focuses on strategic planning and execution in the early-stage biotech sector. At Collage Venture Partners, he played a key role in informing investment decisions and providing operational support to clinical-stage portfolio companies.

 

As a co-founder of Guardian Bio, Richard led the scientific strategy for the venture-backed immune-oncology platform from concept to clinical readiness. His contributions included supporting fundraising, managing partnerships for translational and preclinical programs, and developing early clinical collaborations.

 

Richard holds a Ph.D. in Biomedical Sciences, Immunology, and Cellular Metabolism from the University of Central Florida. He also completed a Postdoctoral Fellowship in Tumor Microenvironment and Immunity at the University of Pennsylvania.

​​

Linda is a seasoned Drug Development Professional with extensive experience in the pharmaceutical and biotechnology industries. She began her career at Parke-Davis, now Pfizer, where she spent over 30 years in pre-clinical and clinical development.

 

With expertise in Clinical Operations and Clinical Trials, Linda has provided strategic leadership toward the development of numerous compounds within the Cardiovascular, Diabetes and Metabolic Disease, Allergy and Respiratory, Neuroscience, Pain, Inflammation, Dermatology, Ophthalmology, Vaccine and Biosimilars Therapeutic Areas. Linda has led Phase I through Phase III and post-marketing programs and has experience in neonate, pediatric, and adult studies.

 

Her areas of expertise include strategic planning and execution of global clinical trials, global portfolio management, regulatory submissions, quality, metrics and inspection readiness, risk assessment and contingency planning. She has extensive experience with CRO, Vendor, and Alliance management as well as Regulatory Authority Sponsor Inspections and Defense.

 

Linda holds a B.S. in Biology and M.S. in Clinical Research and Biostatistics from the University of Michigan.